Olmutinib is an orally active epidermal growth factor receptor inhibitor used to treat T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include olmutinibum, N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3 and 2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide. Its PubChem CID is 54758501.
Olmutinib
| CAS No | 1353550-13-6 |
|---|---|
| Molecular Formula | C26H26N6O2S |
| Molecular Weight | 486.60 g/mol |
| Synonyms | N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Olmutinib is an orally active epidermal growth factor receptor inhibitor used to treat T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals.
The listed CAS number is 1353550-13-6.
The listed molecular formula is C26H26N6O2S.
The listed molecular weight is 486.60 g/mol.
N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide.
The source lists olmutinibum, N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3 and 2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide.